Cannabinoid Receptor Agonists in Cancer: Beyond Palliative Care to Potential Anti-Tumor Effects
A review found that cannabinoids showed predominantly inhibitory effects on tumor growth, migration, angiogenesis, and metastasis in preclinical studies, suggesting potential as curative agents beyond their established palliative uses.
Quick Facts
What This Study Found
This review examined the growing evidence for cannabinoids in cancer treatment, covering both established palliative uses and emerging anti-tumor evidence.
Preclinical studies showed that cannabinoid receptor agonists can limit cell proliferation and induce tumor-selective cell death. Predominantly inhibitory effects were described on tumor growth, migration, blood vessel formation (angiogenesis), metastasis, and inflammation.
However, the review noted a complicating factor: synthetic cannabinoids could also have pro-tumor effects in living organisms due to their immunosuppressive properties, creating a tension between anti-tumor and immune-suppressive effects.
The authors suggested that cannabinoid receptor agonists expressed by tumor cells may offer a novel therapeutic strategy and proposed exploring cannabinoids not just as palliative agents but as potential curative treatments.
Key Numbers
The review covered multiple cannabinoid types and cancer models. Inhibitory effects were described on tumor growth, migration, angiogenesis, metastasis, and inflammation.
How They Did This
Narrative review of preclinical research on cannabinoids and cancer, covering anti-proliferative effects, apoptosis induction, anti-angiogenic properties, anti-metastatic effects, and immunological considerations.
Why This Research Matters
While cannabinoids have been used for cancer-related symptoms (nausea, pain, appetite), the preclinical evidence for direct anti-tumor effects suggested a fundamentally different role in cancer treatment.
The Bigger Picture
The idea that cannabinoids might fight cancer directly, not just manage symptoms, has generated both scientific interest and public excitement. While preclinical evidence was growing in 2009, translating these findings to human cancer treatment has proven challenging.
What This Study Doesn't Tell Us
Evidence was primarily preclinical (cell culture and animal studies). The immunosuppressive properties of cannabinoids could theoretically promote tumor survival. Human cancer is far more complex than animal models suggest.
Questions This Raises
- ?Can anti-tumor effects be achieved at doses tolerable in humans?
- ?How can the tension between anti-tumor and immunosuppressive effects be managed?
- ?Which cancer types are most responsive to cannabinoid treatment?
Trust & Context
- Key Stat:
- Predominantly inhibitory effects on tumor growth, migration, angiogenesis, and metastasis
- Evidence Grade:
- Review of preclinical evidence. Anti-tumor effects demonstrated in cell culture and animal models but not validated in human clinical trials.
- Study Age:
- Published in 2009. Clinical trials of cannabinoids as anti-cancer agents have proceeded slowly, with most human evidence still limited to palliative applications.
- Original Title:
- Use of cannabinoid receptor agonists in cancer therapy as palliative and curative agents.
- Published In:
- Best practice & research. Clinical endocrinology & metabolism, 23(1), 117-31 (2009)
- Authors:
- Pisanti, Simona, Malfitano, Anna Maria(2), Grimaldi, Claudia, Santoro, Antonietta, Gazzerro, Patrizia, Laezza, Chiara, Bifulco, Maurizio
- Database ID:
- RTHC-00380
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Can cannabinoids cure cancer?
Preclinical studies showed cannabinoids can kill cancer cells and inhibit tumor growth in lab settings. However, these results have not been confirmed in human clinical trials. The gap between cell culture effects and human cancer treatment is substantial.
Why might cannabinoids both fight and promote tumors?
Cannabinoids can directly kill tumor cells and inhibit their growth, but they also suppress immune function. Since the immune system helps fight cancer, immunosuppression could theoretically allow some tumors to grow. The net effect likely depends on cancer type and specific cannabinoid used.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-00380APA
Pisanti, Simona; Malfitano, Anna Maria; Grimaldi, Claudia; Santoro, Antonietta; Gazzerro, Patrizia; Laezza, Chiara; Bifulco, Maurizio. (2009). Use of cannabinoid receptor agonists in cancer therapy as palliative and curative agents.. Best practice & research. Clinical endocrinology & metabolism, 23(1), 117-31. https://doi.org/10.1016/j.beem.2009.02.001
MLA
Pisanti, Simona, et al. "Use of cannabinoid receptor agonists in cancer therapy as palliative and curative agents.." Best practice & research. Clinical endocrinology & metabolism, 2009. https://doi.org/10.1016/j.beem.2009.02.001
RethinkTHC
RethinkTHC Research Database. "Use of cannabinoid receptor agonists in cancer therapy as pa..." RTHC-00380. Retrieved from https://rethinkthc.com/research/pisanti-2009-use-of-cannabinoid-receptor
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.